Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Giants Win 2008 China Charity Awards

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Civil Affairs recently announced its 2008 China Charity Award, which recognizes the outstanding achievements of individuals, enterprises and charity programs in 2008. The award represents the most prestigious in the country honoring corporate social responsibility. In the foreign company segment, pharmaceutical and medical device manufacturers Sanofi-Aventis, AstraZeneca, Novartis, Hualan Biological Engineering, Dupromise Medicine, Siemens and Canon China are among the winners. Following the Sichuan earthquake in May this year, Sanofi and Novartis each donated RMB 15 million ($2 million) in cash and medicine, while AstraZeneca allocated some RMB 14.6 million worth of donations, medicine and materials to support post-disaster reconstruction (PharmAsia News, May 19, 2008). (Click here for more - Chinese Language)
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC067490

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel